Aquestive Therapeutics Inc
NASDAQ:AQST
Balance Sheet
Balance Sheet Decomposition
Aquestive Therapeutics Inc
Current Assets | 113.4m |
Cash & Short-Term Investments | 95.2m |
Receivables | 8.3m |
Other Current Assets | 9.9m |
Non-Current Assets | 16.1m |
PP&E | 9.5m |
Intangibles | 1.2m |
Other Non-Current Assets | 5.4m |
Current Liabilities | 18.1m |
Accounts Payable | 10.5m |
Accrued Liabilities | 5.1m |
Other Current Liabilities | 2.5m |
Non-Current Liabilities | 147.8m |
Long-Term Debt | 28.8m |
Other Non-Current Liabilities | 119m |
Balance Sheet
Aquestive Therapeutics Inc
Dec-2005 | Dec-2006 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||
Cash & Cash Equivalents |
1
|
15
|
9
|
17
|
61
|
49
|
32
|
28
|
27
|
24
|
|
Cash Equivalents |
1
|
15
|
9
|
17
|
61
|
49
|
32
|
28
|
27
|
24
|
|
Total Receivables |
0
|
1
|
11
|
6
|
6
|
13
|
7
|
12
|
5
|
8
|
|
Accounts Receivables |
0
|
1
|
11
|
6
|
6
|
13
|
7
|
12
|
5
|
8
|
|
Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Inventory |
1
|
0
|
3
|
4
|
5
|
3
|
2
|
4
|
6
|
7
|
|
Other Current Assets |
0
|
0
|
0
|
1
|
2
|
3
|
3
|
3
|
2
|
2
|
|
Total Current Assets |
2
|
17
|
23
|
28
|
74
|
68
|
45
|
47
|
40
|
41
|
|
PP&E Net |
8
|
9
|
15
|
13
|
12
|
10
|
10
|
8
|
9
|
10
|
|
PP&E Gross |
8
|
9
|
15
|
13
|
12
|
10
|
10
|
8
|
9
|
10
|
|
Accumulated Depreciation |
1
|
2
|
28
|
32
|
35
|
38
|
41
|
40
|
42
|
43
|
|
Intangible Assets |
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
7
|
6
|
5
|
4
|
|
Other Long-Term Assets |
1
|
0
|
1
|
1
|
0
|
0
|
1
|
1
|
1
|
1
|
|
Total Assets |
12
N/A
|
27
+121%
|
39
+45%
|
43
+9%
|
87
+101%
|
78
-10%
|
63
-20%
|
62
-1%
|
57
-8%
|
57
+1%
|
|
Liabilities | |||||||||||
Accounts Payable |
1
|
1
|
7
|
10
|
20
|
12
|
7
|
8
|
10
|
9
|
|
Accrued Liabilities |
0
|
1
|
3
|
4
|
7
|
5
|
9
|
10
|
8
|
7
|
|
Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
5
|
0
|
3
|
2
|
19
|
0
|
|
Other Current Liabilities |
0
|
0
|
1
|
2
|
1
|
1
|
2
|
2
|
3
|
2
|
|
Total Current Liabilities |
2
|
2
|
11
|
15
|
33
|
19
|
21
|
22
|
40
|
18
|
|
Long-Term Debt |
6
|
0
|
78
|
88
|
43
|
60
|
34
|
52
|
33
|
28
|
|
Other Liabilities |
0
|
0
|
8
|
9
|
1
|
6
|
56
|
71
|
103
|
118
|
|
Total Liabilities |
8
N/A
|
2
-75%
|
97
+4 931%
|
112
+16%
|
77
-31%
|
85
+10%
|
111
+32%
|
144
+29%
|
176
+22%
|
164
-7%
|
|
Equity | |||||||||||
Common Stock |
11
|
50
|
50
|
52
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Retained Earnings |
12
|
25
|
109
|
120
|
61
|
130
|
186
|
257
|
311
|
319
|
|
Additional Paid In Capital |
5
|
0
|
1
|
0
|
71
|
124
|
138
|
175
|
193
|
213
|
|
Total Equity |
5
N/A
|
25
+441%
|
57
N/A
|
69
-20%
|
10
N/A
|
6
N/A
|
49
-692%
|
82
-69%
|
119
-44%
|
106
+10%
|
|
Total Liabilities & Equity |
12
N/A
|
27
+121%
|
39
+45%
|
43
+9%
|
87
+101%
|
78
-10%
|
63
-20%
|
62
-1%
|
57
-8%
|
57
+1%
|
|
Shares Outstanding | |||||||||||
Common Shares Outstanding |
15
|
15
|
25
|
25
|
25
|
34
|
35
|
41
|
55
|
69
|
|
Preferred Shares Outstanding |
0
|
38
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|